FOXO4-DRI vs Klotho-Derived Peptide
Research Verdict
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Quick Answers
Which is better, FOXO4-DRI or Klotho-Derived Peptide?
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
What is the key difference between FOXO4-DRI and Klotho-Derived Peptide?
FOXO4-DRI is a senolytic that forces senescent cells into apoptosis by disrupting FOXO4-p53 binding; klotho peptide targets cognitive aging through GluN2B/NMDA signaling - fundamentally different anti-aging approaches.
Evidence Comparison
FOXO4-DRI: Baar et al. 2017 (Cell) demonstrated senolytic activity in aged mice, single research group, no human data. Klotho peptide: Castner et al. 2023 showed cognitive improvement in aged primates, but no fragment-specific human data exists. FOXO4-DRI has the better-characterized preclinical mechanism; klotho has the primate data point.
Evidence Context Favoring FOXO4-DRI
Senescence research targeting selective elimination of senescent cells in aging models.
Evidence Context Favoring Klotho-Derived Peptide
Cognitive aging research where the primate cognition data (Castner 2023) is the relevant evidence anchor.
Side-by-Side Snapshot
| Evidence grade | FOXO4-DRI: Level D Klotho-Derived Peptide: Level D |
|---|---|
| Research status | FOXO4-DRI: Preclinical Klotho-Derived Peptide: Preclinical |
| Primary category | FOXO4-DRI: Anti-Aging & Longevity Klotho-Derived Peptide: Anti-Aging & Longevity |
| Cited studies | FOXO4-DRI: 2 Klotho-Derived Peptide: 4 |